Allogene Therapeutics' Convertible Note Round

Allogene Therapeutics raised a round of funding on September 06, 2018.

Allogene Therapeutics (NASDAQ: ALLO) is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor T-cel…

Articles about Allogene Therapeutics' Convertible Note Round: